JP Morgan Chase
TRDA icon

JP Morgan Chase’s Entrada Therapeutics TRDA Stock Holding History

JP Morgan Chase’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$175K Sell
14,847
-55,914
-79% -$641K ﹤0.01% 5540
2025
Q4 		$727K Sell
70,761
-63,117
-47% -$532K ﹤0.01% 4800
2025
Q3 		$776K Buy
133,878
+117,844
+735% +$689K ﹤0.01% 4762
2025
Q2 		$108K Buy
16,034
+1,328
+9% +$10.7K ﹤0.01% 5570
2025
Q1 		$133K Sell
14,706
-20,764
-59% -$259K ﹤0.01% 5428
2024
Q4 		$613K Buy
35,470
+24,658
+228% +$447K ﹤0.01% 4928
2024
Q3 		$173K Buy
10,812
+242
+2% +$3.81K ﹤0.01% 5471
2024
Q2 		$151K Buy
10,570
+2,157
+26% +$30.7K ﹤0.01% 5303
2024
Q1 		$119K Sell
8,413
-5,741
-41% -$81.2K ﹤0.01% 5597
2023
Q4 		$214K Sell
14,154
-427
-3% -$6.33K ﹤0.01% 5358
2023
Q3 		$230K Sell
14,581
-2,069
-12% -$32.6K ﹤0.01% 4982
2023
Q2 		$252K Buy
16,650
+8,110
+95% +$112K ﹤0.01% 4944
2023
Q1 		$124K Buy
8,540
+947
+12% +$12.6K ﹤0.01% 5332
2022
Q4 		$103K Buy
+7,593
New +$133K ﹤0.01% 5347
2022
Q2 		– Sell
-4,934
Closed -$46K – 6898
2022
Q1 		$46K Buy
4,934
+1,440
+41% +$15.4K ﹤0.01% 5826
2021
Q4 		$60K Buy
+3,494
New +$84.7K ﹤0.01% 5879

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's TRDA Position: Q1 2026 in Review

JP Morgan Chase reduced its Entrada Therapeutics (TRDA) stake by 79% in Q1 2026, selling an estimated $641K and leaving 14,847 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #5540.

JP Morgan Chase first reported a position in TRDA in Q4 2021 and has held it in 16 quarters since. The position peaked at $776K in Q3 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • JP Morgan Chase held 14,847 shares of Entrada Therapeutics worth $175K as of Q1 2026.
  • JP Morgan Chase sold 55,914 Entrada Therapeutics shares in Q1 2026, an estimated $641K.
  • Entrada Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5540 holding.
  • JP Morgan Chase first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • JP Morgan Chase's Entrada Therapeutics position peaked at $776K in Q3 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.